Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.
“In this trial, patients demonstrated a significant improvement in disease with no drug-related hearing impairments, significant hyperglycemia or menstrual changes — a point worth noting as the majority of people living with TED are women,” Raymond Douglas, MD, PhD, chief scientific officer at Sling Therapeutics and professor at Cedars-Sinai Medical Center,